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ith 42 million people now living with HIV/AIDS,
expanding  access  to  antiretroviral  treatment  for
those who urgently need it is one of the most press-
ing challenges in international health. Providing treat-
ment is essential to alleviate suffering and to mitigate the
devastating impact of the epidemic. It also presents unprece-
dented opportunities for a more effective response by involving
people living with HIV/AIDS, their families and communi-
ties in care and will strengthen HIV prevention by increasing
awareness, creating a demand for testing and counselling and
reducing stigma and discrimination.
The challenges are great. Sustainable financing is essential.
Drug  procurement  and  regulatory  mechanisms  must  be
established. Health care workers must be trained, infrastruc-
ture improved, communities educated and diverse stakehold-
ers mobilized to play their part. This series, Perspectives and
Practice  in  Antiretroviral Treatment,  provides  examples  of
how  such  challenges  are  being  overcome  in  the  growing
number of developing countries in which antiretroviral treat-
ment programmes are underway. The case studies and analy-
ses in this series show how governments, civil society organi-
zations, private corporations and others are successfully pro-
viding  antiretroviral  treatment  and  care  to  people  with
HIV/AIDS, even in the most resource-constrained settings.
In documenting these pioneering programmes, WHO hopes
that their experiences will both inform and inspire everyone
who is working to make access to treatment a reality.
W
About This Seriessouthern Africa is the epicentre of the worldwide
AIDS pandemic. South Africa has over five mil-
lion people living with HIV/AIDS, more than any
other  country.  A  comprehensive  response  to
HIV/AIDS — including preventing new infections, prevent-
ing mother-to-child transmission, prophylaxis and treatment
of  opportunistic  infections,  dignified  end-of-life  care  and,
critically,  antiretroviral  therapy  –  is  needed  to  adequately
tackle the epidemic. 
Since 1999, Médecins Sans Frontières (MSF) has been work-
ing in the Khayelitsha township, in Cape Town, initially sup-
porting the first provincial government-run project to pre-
vent  mother-to-child-transmission  in  South  Africa.
Khayelitsha is a poor township with about 500 000 residents.
More than half of the adult population is unemployed, and
most  live  in  informal  housing  (usually  corrugated  iron
shacks). About a quarter of the women at Khayelitsha ante-
natal clinics test HIV-positive. Estimates indicate that more
than 50 000 residents are infected with HIV. 
In  April  2000,  in  collaboration  with  the  Provincial
Administration  of  the  Western  Cape,  MSF  set  up  three
HIV/AIDS  dedicated  clinics  within  Khayelitsha’s  primary
health  care  centers.  In  May  2001,  the  HIV/AIDS  clinics
began to offer ARV treatment to people in an advanced stage
of HIV infection.
The  Khayelitsha  ARV  treatment  project  was  initiated  to
demonstrate  that  treating  HIV/AIDS  with  antiretroviral
(ARV)  drugs  in  a  primary  health  care  setting  and  in  a
resource-limited environment is feasible and replicable. In
addition, it aimed to prove that developing countries can
provide affordable HIV/AIDS care with low-cost ARV drugs.
After two years, the programme has produced invaluable les-
sons, which are outlined in this paper.
«People no longer accept that the sick and dying,simply because they are poor,should be denied
drugs which have transformed the lives of others who are better off.»
– Kofi Annan,United Nations Secretary-General,26 April 2001
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INTRODUCTION
S
KhayelitshaTHE KHAYELITSHA ARV TREATMENT
PROGRAMME:A BRIEF OVERVIEW
The  HIV/AIDS  clinics. The  clinics  are  located  within
community health centres in Khayelitsha. They provide a
comprehensive package of AIDS services that include coun-
selling,  support,  prophylaxis,  treatment  of  opportunistic
infections, ARV treatment and referrals where necessary. The
staff in each clinic initially consisted of one physician, one
professional nurse and one lay counsellor. One nurse and one
counsellor have since joined the clinic teams, to accommodate
the increasing number of patients and to develop a nurse-
based service model much more suitable to the reality of
health services in Africa. The three clinics currently serve over
1800 HIV clients per month. Clients attend with different
regularity according to clinical stage.
Eligibility criteria for ARV treatment. Initiating ARV treat-
ment in a population with a high prevalence of infection and
limited  resources  necessitates  a  patient  selection  process.
Patient selection potentially challenges equity in the delivery
of  the  services,  and  therefore  requires  clearly-defined  and
transparent procedures. 
Eligibility for ARV treatment in the Khayelitsha programme
is determined by criteria that combine an assessment of the
clinical and social conditions of candidates, as well as of their
anticipated ability to adhere to ARV treatment. Only people
who  attend  the  HIV  clinics  regularly  and  who  live  in
Khayelitsha are considered for ARV treatment. To be eligible,
patients need to be in WHO stage III or IV and have CD4
cell counts of less than 200/mm
3. Adherence to co-trimoxa-
zole prophylaxis and tuberculosis treatment and regular clin-
ic attendance are used to assess ability to adhere to the ther-
apy. After the patient has been counselled about ARV treat-
ment, a clinic worker assesses the social and support struc-
tures available by conducting a home visit. The home visit
also verifies the person’s family environment and disclosure
to at least one person who will act as a treatment assistant.
Other factors considered in the decision about initiation of
ARV treatment are history of alcohol abuse, and geographi-
cal instability (Fig. 1).
Enrolment  process. Candidates’  anonymous  dossiers  are
presented to a committee of community members, people
living with HIV/AIDS and clinicians not related to MSF
who make the final decision on enrolment based on the clinical,
social and adherence criteria. The presenting clinician is not
involved in the final decision about enrolment. In a context
where treatment is scarce but urgently needed, this removes
some of the burden from the clinician and integrates the
community into the process. Preference has been given to
people  living  with  HIV/AIDS  based  on  their  number  of
dependants (such as mothers versus single men); health sta-
tus (very sick versus meeting the clinical criteria); income
(very poor versus perhaps soon being able to afford treat-
ment); and disclosure and activism (being open about HIV
status and/or active in community organizations versus refus-
ing to disclose).
Perspectives and practice in antiretroviral treatment
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Figure 1. Selection of candidates
for ARV treatment.
Patients meeting clinical and
biological criteria:stage III and IV
and < 200 CD4 count
Regularity:to have attended HIV
clinics for least 3 months and been
on time for the last 4 visits
Pre-selection by clinicans
Patients meeting social and adherence
criteria:evaluation of home environ-
ment,disclosure,familly support
Final seclection by community
selection committeeInitiation of therapy. Once selected, the person is re-assessed
by  a  physician.  Appropriate  laboratory  tests  are  also  per-
formed to assess subsequent response to ARV treatment and
potential adverse events. Subsequent laboratory monitoring
is conducted according to a simplified schedule (table 1).
Treatment  regimen. Standardized  triple  therapy  regimens
are used. First-line therapy has until now included the com-
bination of zidovudine, lamivudine and either nevirapine or
efavirenz. The choice between efavirenz and nevirapine con-
siders whether the person is receiving tuberculosis treatment,
has abnormal liver function (in which case efavirenz is pre-
ferred) or is pregnant (in which case nevirapine is preferred).
To date 60% of clients have started therapy on efavirenz.
Until recently the second-line regimen has been stavudine,
didanosine and lopinavir with ritonavir. It is likely that stavu-
dine will soon replace zidovudine in the first-line regimen,
with zidovudine replacing stavudine in the second-line.  This
will further simplify laboratory monitoring of the first-line
regimen, and result in fewer adverse events on the second-
line regimen.  
Monitoring  of  progress. Everyone  on  ARV  treatment  is
assessed clinically, weekly for the first 2 weeks, then every 2
weeks until the end of the second month, and monthly there-
after (table 1). Once people are stable on therapy, they can be
assessed every 2 months. All laboratory tests are done at cen-
ters from the National Health Laboratory Services. 
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Table 1.Schedule of visits and laboratory monitoring prior and after initiation
of ARV treatment
M
1 MMMMMMMMM
-0.5 0 0.5 1 2 3 6 12 18 24
All Informed consent X
Rx assistant – X – – – X If VL detectable
CD4 cell count X – – – – – X X X X
HIV RNA X – – – – X X X X X
AZT FBC &Diff X – – X X X X X X X
D4T FBC &Diff X Clinical reasons only
EFV ALAT X Clinical reasons only
NVP ALAT X – X X X – X X X X
PICholesterol/Tryglyceride X – – – – – X X – –
1.M:months (M=O refers to initiation of ARV treatment).
Nurse and patient during follow-up visit.Nurses do most
of the follow-up work.Note the pill-box in front of the patient:
a device to enhance adherence.CLINICAL OUTCOMES
A preliminary analysis of those initiating treatment between
April 2001 and late 2002 included 288 adults naïve to prior
ARV  therapy.  The  median  age  at  baseline  was  31  years
(interquartile  range  28–37)  and  70%  were  women.  The
median follow-up time was 6.5 months.
Clinical measures at baseline. The median weight at base-
line was 57 kg. The median CD4 cell count was 42 cells per
mm
3, reflecting that many people initiated ARV treatment at
a very advanced stage of disease progression. The mean log
10
viral load at baseline was 5.2. Half had a prior diagnosis of
AIDS on initiating therapy.
Clinical measures after initiation of ARV TREATMENT.
After 1 year on treatment, the mean weight gain was 10 kg.
The frequency of opportunistic infections declined dramati-
cally after initiation of ARV treatment. The incidence rate of
tuberculosis and oral or oesophageal candidiasis – 2 of the
most  frequent opportunistic infections - declined by two
thirds  for  both  diseases  when  comparing  for  the  same
patients the period from before initiation of ARV treatment
to the period on ARV treatment.
After 6 months, 88% of those on ARV treatment had unde-
tectable viral load levels (below 400 copies/ml), and 83%
had sustained viral load suppression after 1 year on ARV
treatment.
The mean CD4 cell count at 12 months of treatment was
275 cells per mm3. The mean overall increase of CD4 cell
count was 221 cells per mm
3. Increases were higher in those
with a lower CD4 count at baseline.  
Treatment changes and adverse events. Most people toler-
ated the first-line regimen well. Fourteen percent changed
one of the ARV drugs because of either adverse events or a
contraindication to treatment with that drug. The incidence
of adverse events severe enough to require change in treat-
ment was uniformly low, with 8% of patients needing to
change  an  individual  drug  due  to  adverse  events  (usually
attributed to either zidovudine or nevirapine). Three patients
had been changed to a second-line regimen by the end of 2002.
Health-related quality of life. An ongoing study is measur-
ing pain and discomfort, anxiety and depression, mobility,
self-care and usual activity in both the MSF clinics and the
general population. At the start of treatment, all domains
except anxiety and depression differed significantly between
the cohort on ARV treatment and the community sample.
Over time, the health-related quality of life of those on treat-
ment  approached  that  of  the  community  sample  in  all
domains, until at 6 months the ARV treatment and commu-
nity populations did not differ significantly.
Survival. Survival  at  18  months  on  treatment  was  84%
(95% confidence interval 79–89%). All deaths among peo-
ple who had started ARV treatment were attributed to AIDS
and none to treatment complications. Three quarters of the
deaths occurred before 3 months on treatment, with dramat-
ically  reduced  mortality  rates  after  this  time  regardless  of
initial CD4 count (Fig. 2). This is primarily because treat-
ment was initiated late, as many were already at quite an
advanced  stage  of  HIV/AIDS  when  they  arrived  at  the
clinics. Despite this, even the group that started treatment
late did remarkably well.
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Table 2:Selected Treatment outcomes
Duration on treatment
6 months 12 months
Mean weight gain (kg) 6.1 10.0
Proportion of those tested 
with undetectable viral load 88% 83%
Mean CD4 cell count 
change for those with  +°133 +°221
serial measurements cells/ l cells/ l
Proportion surviving 88% 84%ADHERENCE
ARV treatment requires good adherence to achieve sustained
suppression of viral replication and to prevent the onset of
resistance. Because ARV treatment is a life-long treatment, it
requires commitment and a responsible attitude. In this pro-
gramme, the key to achieving this commitment has been to
implement two equally important strategies:
◗ using simplified and standardized regimens
that minimize the burden of pills, the dosages
and the risk of side effects; and
◗ implementing a solid patient-centered education 
approach that ensures a good understanding
of the treatment by the patient and a strong
support system.
To achieve good understanding of ARV treatment and suffi-
cient support, MSF has developed an education programme
focusing on the people living with HIV/AIDS that combines
several components.
◗ Individual support: Everyone who enrolls in the ARV
treatment  programme  is  required  to  identify  a  treatment
assistant. The treatment assistant is usually someone living in
the household, aware of the person’s status and willing to
assist with medication as necessary. Lay counsellors – trained
in HIV/AIDS and ARV treatment – are available in the clin-
ics to help people living with HIV/AIDS with individualized
adherence plans that respond to their specific needs. In case
of serious adherence problems, a nurse–counsellor performs
home visits as needed for more thorough follow-up.
◗ Peer support: Twice a month, the clinics host support
groups attended exclusively by people on ARV treatment.
Participants  discuss  barriers  to  adherence,  adverse  events,
disclosure and other psychosocial issues that affect them. A
counsellor regularly performs adherence workshops in the
support groups.
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Fig.2. Survival of adults on ARV treatment by initial CD4 count cathegory
CD4 >= 50 cells/ul
CD4 < 50 cells/ul
p=0.0118
Baseline Duration on treatment in months
(cells/ml)
At risk
>= 50 127 99 70 46 28 20 6$
< 50 154 103 78 51 36 25 11
Survival %
>= 50 95.9 92.8 89.7 89.7 89.7 89.7
< 50 84.8 83.1 80.8 79 79 79
Survival of adults on antiretroviral therapy by initial CD4 cell count category
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g◗ Materials support: People in therapy are provided with
pillboxes  and  drug  identification  charts,  daily  schedules,
diaries  and  educational  materials  explaining  the  risks  and
benefits of ARV treatment.
Combining simplified regimens with a low pill burden and a
comprehensive individual support programme, beneficiaries
of the Khayelitsha ARV treatment programme show high lev-
els of adherence to the medication. A clinic-based self-report-
ed evaluation of adherence to ARV treatment is currently
ongoing, based on a 4-day recall period. Preliminary results
show that 89% of respondents indicate adherence exceeding
95% at 3 months on treatment. 
THE NEW SOCIAL CONTRACT:
BREAK THE FATALITY AND WE WILL
BREAK THE SILENCE
The HIV services in Khayelitsha in recent years were devel-
oped alongside strong civil society pressure and community-
based  education  programmes.  The  Treatment  Action
Campaign (TAC), a grassroots HIV advocacy organization,
has acted on a provincial and national level, mobilising the
community to be aware of HIV as a political issue and pres-
surising  the  government  to  develop  a  comprehensive
response. The  community  programmes  of  the TAC  have
educated many in the community about HIV/AIDS, pre-
vention  and  ARV  therapy  (“treatment  literacy”).  In
Khayelitsha, the link between education and treatment can
best be described as an new social contract: the clinics pro-
vide effective HIV/AIDS care and life-saving treatment, and
the community breaks the silence, fights stigma and dis-
crimination and, through education, promotes understand-
ing and prevention.
In  Khayelitsha,  TAC’s  Project  Ulwazi (“knowledge”)  has
brought people living with HIV/AIDS, some being treated
through the MSF programme, into schools, clinics, church-
es and workplaces and on radio programmes. Through this
programme, youth have been proactively involved in edu-
cating  the  community,  provoking  discussion,  decreasing
stigma and promoting disclosure. With a mobile exhibition,
Project Ulwazi volunteers have guided hundreds of school-
children, support groups and community members through
a travelling collection of banners, posters, videos and educa-
tional materials showing pictures and live stories of people
living with HIV/AIDS. Project Ulwazi volunteers have also
helped to establish AIDS Action Committees in secondary
schools to continue in-school education beyond the initial
workshops conducted by the volunteers.
This  education  and  awareness-raising  has  been  critical  in
preparing the community to accept treatment, especially as the
national government continues to offer mixed messages on the
benefits of ARV therapy. Treatment, for its part, has motivated
people to listen to educational messages and has promoted a
more open climate for discussion, helping to provoke greater
change on a broader scale.
TREATMENT AND PREVENTION:
TWO SIDES OF THE SAME COIN
In 1999, a provincial initiative on the prevention of mother-to-
child transmission in the Western Cape led to a dramatic increase
in the number of women aware of their HIV status. Before such
programmes existed in the Western Cape, few were aware of their
status and even fewer were willing to disclose it. Prevention of
mother-to-child transmission provided motivation for pregnant
women to be tested for HIV. In 2000, the opening of the MSF
dedicated HIV clinics provoked a similar effect. By providing
effective treatment for opportunistic infections and, for those in
the late stages of HIV/AIDS, ARV therapy, these clinics likewise
provided an incentive for others to be tested: their own health
and survival depended on acknowledging that their recurring ill-
nesses were linked to a larger disease.
The Khayelitsha ARV programme is thus part of an increasing
number  of  initiatives  in  the  Western  Cape  responding  to
HIV/AIDS.  The  government  programmes  range  from  the
expansion of voluntary counselling and testing sites, the develop-
ment of youth clinics to respond to the distinct needs of adoles-
cents, the availability of post-exposure prophylaxis for rape sur-
vivors in government clinics and the universal expansion of pro-
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HIV positive clients discuss their treatment and life experiences in a meetinggrammes in public health facilities to prevent mother-to-child
transmission. The combination of all these initiatives has helped
to create an environment where people feel cared-for. This has
affected prevention, promoting openness and decreasing the stig-
ma around HIV/AIDS.
A 2002 study conducted by the Centre for AIDS Development,
Research and Evaluation and the South African Department of
Health targeted nine commuter sites in South Africa, including
Khayelitsha, and found that Khayelitsha residents reported the
highest levels of condom use, willingness to use a female condom,
willingness to have an HIV test and desire to join an AIDS club
1.
This difference can be largely attributed to the comprehensive
approach to AIDS care, and critically to the inclusion of ARV
treatment which has seen increase in uptake of voluntary coun-
selling and testing in the district from fewer than 1000 HIV tests
in 1998 to more than 12 000 in 2002. The number of HIV sup-
port groups in Khayelitsha has also increased dramatically: from
4 in 1998 to 22 in 2002.
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The availability of ARV treatment in Khayelitsha has demonstrated
that treatment is important for prevention because it:
◗ provides a motivation for HIV-positive people to be aware of their status:without treatment
as an option,knowledge that one is HIV-positive can be seen as offering little
more than stigmatization;
◗ promotes openness and reduces stigma,as HIV is no longer an inevitable death sentence;
◗ can fuel educational initiatives supported by a pool of HIV-positive people open about their status;
◗ improves the morale of health care workers who can offer something beyond temporary
treatment for opportunistic infections;and
◗ helps to keep families intact and economically stable, thereby protecting the most vulnerable 
(women and children) and minimizing at-risk populations.
1 Parker W et al. On the move:  the response of public transport commuters to HIV/AIDS in South Africa.
Johannesburg, Centre for AIDS Development, Research and Evaluation, 2002 (http://www.cadre.org.za,
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AFFORDABILITY OF ARV TREATMENT
Aiming in part to demonstrate the affordability of providing
ARV treatment in a resource-limited setting, the Khayeltisha
ARV  treatment  programme  is  implementing  strategies  to
minimize costs. The importation of generic drugs from over-
seas manufacturers dramatically reduced the costs of treat-
ment.  As  few  generic  ARV  drugs  are  registered  in  South
Africa,  MSF  obtained  permission  from  the  South  African
Medicines Control Council under the Medicines Act (Section
21)  for  the  use  of  unregistered  generic  ARV  drugs.
Authorization required sufficient evidence about drug quality.
Following a collaboration agreement between MSF and the
Brazilian government, MSF started to source generic versions
of ARV drugs for its Khayelitsha project from the Brazilian
state manufacturer, FarManguinhos, in January 2002. The
price of the first-line regimen (zidovudine/lamivudine and
nevirapine) was then US$ 1.55 per person per day. This price
was half the cost of the lowest possible price offered by the
proprietary companies to governments (US$ 3.00  per per-
son per day) and nearly a quarter of the price in the private
sector (US$ 5.50 per person per day). Later in 2002, the
price of this Brazilian combination dropped further to US$
1.08 per person per day.
MSF recently received authorization from the South African
Medicines Control Council to source drugs from different
manufacturers worldwide, opening the chances to get the
lowest prices.
Simultaneously, we have worked with the National Health
Laboratory Services to reduce the price of laboratory tests,
especially viral load and CD4 count. The development of the
pan-leucogating protocol (AffordCD4™) and its immediate
implementation at the National Health Laboratory Services
allowed a price reduction from US$ 24 per test to US$ 8.30
per  test.  Negotiations  between  the  National  Health
Laboratory Services and the proprietary companies that pro-
duce viral load kits led to a slight decrease of the cost of viral
load  testing  in  the  public  sector  (US$  45  per  test).  MSF
believes that the price of viral load testing can still be cut dra-
matically when companies apply the offers to which they have
committed. The target cost for the package of two viral loads
and two CD4 counts in the public sector is US$ 70 per year.
By using generic ARV drugs and reducing the price of labora-
tory tests, MSF has cut the annual real cost per person of ARV
treatment from US$ 1366 in January 2002 to US$ 536 in
April 2003 (adjusted to fluctuations of exchange rate). This
price  is  based  on  the  regimen  zidovudine/  lamivudine  and
nevirapine, and two viral load tests and two CD4 tests per year. 
LESSONS LEARNED:ESSENTIAL
COMPONENTS OF AN EFFECTIVE
HIV/AIDS TREATMENT PROGRAMME
«The doubters said it was impossible, too expensive or impracti-
cal. Let them say that to our patients who are under ARV treat-
ment  and  thriving  in  Khayelitsha. The  challenge  now  is  to
repeat this and to use successful pilot programmes as a guide to
scale up.» 
- Tito August, physician working in the township of Khayelitsha
The  experience  of  the  Khayelitsha  ARV  treatment  pro-
gramme in South Africa yields several lessons. Although indi-
vidual  contexts  necessitate  different  models,  an  effective
HIV/AIDS treatment programme is defined by its capacity
to quickly and effectively treat a substantial number of peo-
ple living with HIV/AIDS.
In the most-affected countries, this can be achieved if:
1. the  public health system is mobilized and AIDS treatment 
activities are integrated into the basic package of care, 
including voluntary counselling and testing (VCT),
prophylaxis of opportunistic infections,
and psychosocial support;
2.treatment services are decentralized down to the primary 
care level to assure both coverage and community
involvement;
3.simple regimens with standardised clinical guidelines 
sequencing the use of drugs and managing adverse events 
encourage ease of adherence for the patient and follow-up 
for the health care professionals;
Demonstration for treatment access at the opening of parliament,
19 February 2003.Note participation of ANC member (wearing party vest)10 ANTIRETROVIRAL THERAPY IN  PRIMARY HEALTH CARE South African Experience - july 03
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4. multidisciplinary teams, including nurse-based care
with a major emphasis on psychosocial support,
utilises available resources and forces a holistic management
of HIV/AIDS;
5. comprehensive approach to adherence includes counsellors,
support groups and significant treatment literacy;
6.a community-based educational programme, incorporating 
basic HIV/AIDS education and a treatment literacy
component, explaining the value and use of ARV drugs, 
complements a treatment programme;
7. the cost of ARV treatment can be made more manageable 
by for example use of generic drugs and inexpensive
laboratory monitoring techniques minimize the cost
of treatment, allowing more to receive ARV treatment
at a manageable cost.
In Khayelitsha, many challenges remain ahead as the pro-
gramme extends into its third year of treatment provision.
1. Consolidation of nurse-based care: Because of human 
resource availability, a developing country treatment model 
must rely heavily on nurses. This can be successfully 
achieved with simplified regimens and management
guidelines.  In Khayelitsha, clinics were initially managed
by a team of one doctor, one nurse, and one counselor.  
The teams currently consist of one doctor, two nurses,
and two counselors.
2.Strengthening of training activities: Training activities 
targeting clinical staff at the primary care level are needed
to ensure that an HIV/AIDS patient is properly cared for 
from an early stage.  MSF in Khayelitsha has organized
two annual trainings of nursing staff in the community 
health centers, to educate about opportunistic infections 
and referrals, and to encourage a unified response
to HIV/AIDS.
3.Integration of  HIV/AIDS and TB services: According
to the World Health Organization, tuberculosis
is at «emergency» levels if the incidence is above 400
per 100,000 p-y.  In Khayelitsha, the incidence of TB
is more than four times that figure, with more than half
of the TB sufferers co-infected with HIV. An effective
intervention to address TB and HIV necessitates
an exploration of the possibility to integrate both services. 
The Khayelitsha clinics are currently aiming to develop
a model of integration.
4.Development of an education programme to support 
long-term adherence to ARV TREATMENT:
The adherence-support programme used in Khayelitsha
up to now has proven to be effective to achieve high levels 
of adherence and viral suppression in the first year
of treatment. Later stages of treatment might require
a different approach to adherence-support as patients begin 
to feel healthier and more distanced from the negative 
effects of their illness. Counselors in Khayelitsha
are implementing separate support groups to respond 
specifically to the issues affecting patients on treatment
for one year or longer.
5. Addressing the specific challenges of paediatric AIDS. 
In wealthy countries paediatric HIV/AIDS is virtually
non-existent, largely due to the success of antiretroviral
therapy. With research priorities shaped by the disease
burden of wealthier countries, there has been relatively little
effort into simplifying paediatric formulations. Currently 
available formulations hardly include any fixed-drug
combination, which complicates administration and
thus adherence. They also pose problems of adjusting
and measuring dosages. On the psychosocial component, 
paediatric AIDS needs specific adherence support
programmes to address the challenges faced by care givers 
and children. These issues are currently being explored
in Khayelitsha.
6.Development of a model of implementation
of ARV treatment in a rural remote setting in SA: 
The development of a successful ARV treatment program 
in the poor peri-urban setting of Khayelitsha is a significant 
achievement, yet many of those infected with HIV in South
Africa live in rural areas.  Implementing a comprehensive 
HIV/AIDS programme with antiretroviral therapy in
a rural area brings unique challenges, most notably
infrastructure constraints and limited human resources. 
Using the experience of Khayelitsha and that of other MSF 
programmes elsewhere in rural Africa, MSF is currently 
developing a model of implementation of HIV/AIDS care, 
including ARV treatment, in a rural area of the Eastern 
Cape province.For further information,contact:
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